Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region

被引:4
|
作者
Dallavalle, Sabrina [1 ,2 ]
Princiotto, Salvatore [1 ]
Mattio, Luce M. [1 ]
Artali, Roberto [3 ]
Musso, Loana [1 ]
Avino, Anna [4 ]
Eritja, Ramon [4 ]
Pisano, Claudio [5 ]
Gargallo, Raimundo [6 ]
Mazzini, Stefania [1 ]
机构
[1] Univ Milan, Dept Food Environm & Nutr Sci DEFENS, I-20133 Milan, Italy
[2] Natl Inst Fundamental Studies, Kandy 20000, Sri Lanka
[3] Scientia Advice Roberto Artali, I-20832 Desio, Italy
[4] CSIC, Networking Ctr Bioengn Biomat & Nanomed CIBER BBN, Inst Adv Chem Catalonia IQAC, Barcelona 08034, Spain
[5] Biogem, Res Inst, I-83100 Avellino, Italy
[6] Univ Barcelona, Dept Chem Engn & Analyt Chem, Barcelona 08028, Spain
关键词
NMR spectroscopy; CD; G-quadruplex; molecular modeling; PARP1; inhibitors; fluorescence titration; promoter; dual-targeting; PARTICLE MESH EWALD; MOLECULAR-DYNAMICS; FORCE-FIELD; INTEGRATION; ALGORITHM; BINDING;
D O I
10.3390/ijms22168737
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DNA repair inhibitors are one of the latest additions to cancer chemotherapy. In general, chemotherapy produces DNA damage but tumoral cells may become resistant if enzymes involved in DNA repair are overexpressed and are able to reverse DNA damage. One of the most successful drugs based on modulating DNA repair are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. Several PARP1 inhibitors have been recently developed and approved for clinical treatments. We envisaged that PARP inhibition could be potentiated by simultaneously modulating the expression of PARP 1 and the enzyme activity, by a two-pronged strategy. A noncanonical G-quadruplex-forming sequence within the PARP1 promoter has been recently identified. In this study, we explored the potential binding of clinically approved PARP1 inhibitors to the G-quadruplex structure found at the gene promoter region. The results obtained by NMR, CD, and fluorescence titration confirmed by molecular modeling demonstrated that two out the four PARP1 inhibitors studied are capable of forming defined complexes with the PARP1 G-quadruplex. These results open the possibility of exploring the development of better G-quadruplex binders that, in turn, may also inhibit the enzyme.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] A single nucleotide variant of human PARP1 determines response to PARP inhibitors
    Cashman, Rivki
    Zilberberg, Alona
    Priel, Avner
    Philip, Hagit
    Varvak, Alexander
    Jacob, Avi
    Shoval, Irit
    Efroni, Sol
    NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [32] Discovery of quinazolinedione derivatives as potent PARP1 inhibitors
    Liu, Dong
    Gong, Aishen
    He, Kan
    Luu, Truc
    Xu, Lucy
    Zhang, Jiayin
    Zhang, Lei
    Zhang, Lianshan
    Zhang, Minsheng
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [33] Clinical indications of PARP1 inhibitors and other targets
    Telli, M. L.
    CANCER RESEARCH, 2020, 80 (04)
  • [34] Discovery of naphthacemycins as a novel class of PARP1 inhibitors
    Shen, Wenbin
    Lu, Xinhua
    Zhu, Jingtong
    Mu, Yunlong
    Xu, Yan
    Gao, Jian
    Zhang, Xuexia
    Zheng, Zhihui
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (15) : 1904 - 1908
  • [35] PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
    Abecassis, Irina
    Sedgewick, Andrew J.
    Romkes, Marjorie
    Buch, Shama
    Nukui, Tomoko
    Kapetanaki, Maria G.
    Vogt, Andreas
    Kirkwood, John M.
    Benos, Panayiotis, V
    Tawbi, Hussein
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [36] Rational design and synthesis of new PARP1 inhibitors
    Romashov, Leonid V.
    Zeifman, Alexey A.
    Zakharenko, Alexandra L.
    Novikov, Fedor N.
    Stroilov, Viktor S.
    Stroganov, Oleg V.
    Chilov, Germes G.
    Khodyreva, Svetlana N.
    Lavrik, Olga I.
    Titov, Ilya Yu.
    Svitan'ko, Igor V.
    MENDELEEV COMMUNICATIONS, 2012, 22 (01) : 15 - 17
  • [37] PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy
    Irina Abecassis
    Andrew J. Sedgewick
    Marjorie Romkes
    Shama Buch
    Tomoko Nukui
    Maria G. Kapetanaki
    Andreas Vogt
    John M. Kirkwood
    Panayiotis V. Benos
    Hussein Tawbi
    Scientific Reports, 9
  • [38] Characterization of PARP1 binding to c-KIT1 G-quadruplex DNA: Insights into domain-specific interactions
    Singh, Dagur Hanuman
    Deeksha, Waghela
    Rajakumara, Eerappa
    BIOPHYSICAL CHEMISTRY, 2024, 315
  • [39] Talazoparib (BMN-673) possesses greater PARP1 trapping activity than structurally distinct PARP inhibitors with identical PARP1 binding properties
    Hopkins, Todd A.
    Shi, Yan Y.
    DiGiammarino, Enrico L.
    Panchal, Sanjay C.
    Zhu, Gui-Dong G.
    Penning, Thomas D.
    Johnson, Eric F.
    Maag, David
    CANCER RESEARCH, 2015, 75
  • [40] Expression of PARP1 Gene in Breast Cancer Patients
    Ulasli, Mustafa
    Gurses, Serdar
    Cengiz, Beyhan
    Oztuzcu, Serdar
    Balakan, Ozan
    Suner, Ali
    Gogebakan, Bulent
    Igci, Mehri
    Balik, Ahmet
    Arslan, Ahmet
    Camci, Celalettin
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (04): : 213 - 218